1. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model
- Author
-
Huang, Rongqin, Ke, Weilun, Liu, Yang, Wu, Dongdong, Feng, Linyin, Jiang, Chen, and Pei, Yuanying
- Subjects
- *
PARKINSON'S disease treatment , *GENE therapy , *LACTOFERRIN , *NANOPARTICLES , *ROTENONE , *BRAIN diseases , *BLOOD-brain barrier , *PARKINSON'S disease , *ANIMAL models in research , *DISEASE risk factors - Abstract
Abstract: Background: Gene therapy is considered one of the most promising approaches to develop an effective treatment for Parkinson''s disease (PD). The existence of blood-brain barrier (BBB) significantly limits its development. In this study, lactoferrin (Lf)-modified nanoparticles (NPs) were used as a potential non-viral gene vector due to its brain-targeting and BBB-crossing ability. Methods and results: The neuroprotective effects were examined in a rotenone-induced chronic rat model of PD after treatment with NPs encapsulating human glial cell line-derived neurotrophic factor gene (hGDNF) via a regimen of multiple dosing intravenous administration. The results showed that multiple injections of Lf-modified NPs obtained higher GDNF expression and this gene expression was maintained for a longer time than the one with a single injection. Multiple dosing intravenous administration of Lf-modified NPs could significantly improve locomotor activity, reduce dopaminergic neuronal loss, and enhance monoamine neurotransmitter levels on rotenone-induced PD rats, which indicates its powerful neuroprotective effects. Conclusion: The findings may have implications for long-term non-invasive gene therapy for neurodegenerative diseases in general. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF